HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans
出版年份 2010 全文链接
标题
HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans
作者
关键词
-
出版物
JOURNAL OF CLINICAL INVESTIGATION
Volume 120, Issue 10, Pages 3578-3593
出版商
American Society for Clinical Investigation
发表日期
2010-09-18
DOI
10.1172/jci42442
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis
- (2010) P. Koppikar et al. BLOOD
- Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia
- (2009) L. J. Russell et al. BLOOD
- The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors
- (2009) Michael Hedvat et al. CANCER CELL
- Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera
- (2009) Alfonso Quintás-Cardama et al. JOURNAL OF CLINICAL ONCOLOGY
- Rearrangement of CRLF2 in B-progenitor– and Down syndrome–associated acute lymphoblastic leukemia
- (2009) Charles G Mullighan et al. NATURE GENETICS
- A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6–dependent B cell lymphomas
- (2009) Leandro C Cerchietti et al. NATURE MEDICINE
- Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models
- (2009) E. Caldas-Lopes et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia
- (2009) A. Yoda et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms
- (2008) C. S. Tam et al. BLOOD
- Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice
- (2008) S. Xing et al. BLOOD
- Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
- (2008) J.-J. Kiladjian et al. BLOOD
- MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort
- (2008) P. A. Beer et al. BLOOD
- Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera
- (2008) Gerlinde Wernig et al. CANCER CELL
- Inhibition of Hsp90 Down-regulates Mutant Epidermal Growth Factor Receptor (EGFR) Expression and Sensitizes EGFR Mutant Tumors to Paclitaxel
- (2008) A. Sawai et al. CANCER RESEARCH
- Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma
- (2008) D. B. Solit et al. CLINICAL CANCER RESEARCH
- Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice
- (2007) R. Tiedt et al. BLOOD
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started